Everything continues to come up Eli Lilly. The company has now matched its rival Novo Nordisk with an FDA approval for its drug to reduce cardiovascular risk in people who also have a metabolic indication.

Mounjaro—Lilly’s tirzepatide-based type 2 diabetes (T2D) drug—is the first GIP and GLP-1 receptor agonist proven to lower heart attack, stroke or cardiovascular death risk in adults with T2D at high risk for these events, the company said in a press release on Friday. Mounjaro was already indicated as an adjunct to diet and exercise to improve blood sugar for people 10 years and older with T2D.

With the FDA greenlight, Mounjaro joins Novo’s semaglutide drugs Ozempic and Wegovy in the cardiovascular space. Wegovy was approved in March 2024 for adults with heart disease and overweight or obesity, while Ozempic is approved to reduce the risk of major adverse cardiovascular events in adults with T2D and established cardiovascular disease. Semaglutide targets and activates the GLP-1 receptor alone.